Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Carvedilol vs beta‐blocker

All‐cause mortality · adults with cirrhosis and gastroesophageal varices

Carvedilol showed no clear difference in mortality compared with traditional, non‐selective beta‐blockers (low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.86 [0.48, 1.53]
7 studies · 507 participants
Low

Carvedilol vs beta‐blocker

Upper gastrointestinal bleeding · adults with cirrhosis and gastroesophageal varices

It is very uncertain whether carvedilol changes upper gastrointestinal bleeding compared with traditional, non‐selective beta‐blockers (very low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.77 [0.43, 1.37]
10 studies · 810 participants
Very low

Carvedilol vs beta‐blocker

Serious adverse events · adults with cirrhosis and gastroesophageal varices

Carvedilol showed no clear difference in serious adverse events compared with traditional, non‐selective beta‐blockers (low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.97 [0.67, 1.42]
10 studies · 810 participants
Low

Carvedilol vs beta‐blocker

Non‐serious adverse events · adults with cirrhosis and gastroesophageal varices

It is very uncertain whether carvedilol changes non‐serious adverse events compared with traditional, non‐selective beta‐blockers (very low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.55 [0.23, 1.29]
6 studies · 596 participants
Very low

Carvedilol vs beta‐blocker

Hepatic venous pressure gradient at end of treatment (mmHg) · adults with cirrhosis and gastroesophageal varices

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 368 participants
Low

Carvedilol vs beta‐blocker

Reduction in hepatic venous pressure gradient (%) · adults with cirrhosis and gastroesophageal varices

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 368 participants
Low

Carvedilol vs beta‐blocker

Haemodynamic treatment failure · adults with cirrhosis and gastroesophageal varices

It is very uncertain whether carvedilol changes haemodynamic treatment failure compared with traditional, non‐selective beta‐blockers (very low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.76 [0.57, 1.02]
6 studies · 368 participants
Very low